Zurich, Switzerland

Oliver Floegel

This inventor holds 1 USPTO granted patent and 2 published patent applications and 1 EPO patent. Top assignee: Janssen Pharmaceutica Nv. Active years: 2020.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2020

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Oliver Floegel: Innovator in Ketamine Preparation

Introduction

Oliver Floegel is a notable inventor based in Zurich, Switzerland. He has made significant contributions to the field of pharmaceuticals, particularly in the preparation of ketamine. His work has implications for both medical and therapeutic applications.

Latest Patents

Oliver Floegel holds a patent for the (S)-CSA salt of S-ketamine, (R)-CSA salt of S-ketamine, and processes for the preparation of S-ketamine. This invention focuses on methods for preparing esketamine and resolving S-ketamine from racemic or enantiomerically enriched mixtures. The patent also details the (S)-CSA salt of S-ketamine, specifically in its monohydrate form, as well as the (R)-CSA salt of R-ketamine. He has 1 patent to his name.

Career Highlights

Oliver Floegel is associated with Janssen Pharmaceutica NV, a leading company in the pharmaceutical industry. His work there has been instrumental in advancing the understanding and application of ketamine in various medical contexts.

Collaborations

Throughout his career, Oliver has collaborated with esteemed colleagues, including Cheng Yi Chen and Michael Justus. These partnerships have fostered innovation and contributed to the success of his projects.

Conclusion

Oliver Floegel's contributions to the field of pharmaceuticals, particularly in the preparation of ketamine, highlight his role as an influential inventor. His work continues to impact the medical community and advance therapeutic options.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…